  
|
|
|
 |
2004 |
|
|
December 20, 2004
|
MethylGene Initiates Phase I HDAC Cancer Trial in Hematological Malignancies
|
October 27, 2004
|
MethylGene Announces Third Quarter 2004 Results
|
October 21, 2004
|
MethylGene Third Quarter Results Conference Call Notice
|
October 12, 2004
|
MethylGene to Present at the Bio Emerging Company Investor Forum 2004 in San Francisco
|
October 6, 2004
|
MethylGene Initiates MG98 Phase II Trial in Metastatic Renal Cell Cancer
|
September 30, 2004
|
MethylGene Discloses Preclinical and Clinical Research Data at the 16th EORTC-NIC-AACR Cancer Symposium in Geneva
|
August 30, 2004
|
MethylGene Announces Exercise of Over-allotment Option
|
July 20, 2004
|
MethylGene Announces Second Quarter 2004 Results
|
July 15, 2004
|
MethylGene Issued Histone Deacetylase (HDAC) Patent
|
July 14, 2004
|
MethylGene Second Quarter Results Conference Call Notice
|
July 13, 2004
|
MethylGene and EnVivo Pharmaceuticals to Collaborate in Neurodegenerative Diseases
|
June 29, 2004
|
MethylGene completes initial public offering - Shares listed for trading on the TSX under the symbol "MYG"
|
June 21, 2004
|
MethylGene files final prospectus for initial public offering
|
March 30, 2004
|
MethylGene Discloses Cancer-causing HDAC Isoform
|
March 29, 2004
|
Further preclinical evidence of synergy and molecular activity of MG98, a novel anticancer compound, disclosed at 2004 AACR.
|
|
|
 
|
|
 |
|
